Introduction
a mutation leading to substitution of Arg306 with Thr (Arg306 Thr).
In Caucasians, the prevalence of APC resistance was A-V shunt thrombosis is a well known complication found to range from 1 to 12%, whereas it is rarely in haemodialysis patients although thrombotic events found in other ethnic groups such as Asian populaare uncommon in these patients probably due to the tions [10] [11] [12] . antithrombophilic status in uraemia. APC resistance FV Leiden is found in up to 20% of all cases of and protein S deficiency recently were exposed as deep vein thrombosis (DVT ) [13] . It is the most independent risk factors for thromboembolic events common genetic cause of thrombophilia. It is found [1,2]. Here we report the case of a young female in 50% of cases of DVT with a family history and in patient suffering from multiple thrombotic events of 60% of pregnancy associated thromboses. The APC her A-V shunt due to a combination of APC resistance resistance increases the risk of thrombosis in users of and acquired protein S deficiency.
oral contraceptives 30-fold [14] . The relative risk in a population without any other risk factor is estimated APC resistance to be increased 7-fold for heterozygous individuals and Protein C is a vitamin K-dependent serine protease 80-fold in homozygous subjects. These patients experiwhich inactivates factor Va (FVa) and FVIIIa after ence their thrombosis at a much younger age (31 vs. activation to activated protein C (APC ) by thrombin. 44 years) [15] . Normally, FVa is inactivated by an initial cleavage of
The heterozygous inheritance of both FV deficiency the peptide bond on the carboxyl side of Arg506 and APC resistance is called pseudohomozygocity. followed by a second cleavage at Arg306. The FV These patients show the phenotypic picture of a Leiden mutation is characterized by a single cleavage homozygous APC resistance, but have a FV level at Arg506 (see Figure 1) . This results in a 10-fold about half of normal [16 ] . Some authors also report slower inactivation of FVa [3] . The resistance to APC cases of cerebral venous thrombosis [17, 18] . An was discovered by Dahlback et al. when they were association of APC resistance with artery embolism is unable to observe the expected prolongation of the unlikely [19] . partial thrombo plastin time after adding exogenous APC to the plasma of a middle-aged man [4] . Bertina Protein S deficiency et al. identified the molecular defect as a point mutation Protein S inhibits coagulation by serving as a cofactor in FV one year later [5] . The mutation was a G to A for activated protein C. Protein S is a vitamin substitution at nucleotide 1691 resulting in the replace-K-dependent plasma protein synthesized in the liver, ment of arginine at position 506 by glutamine. The vascular endothelium and megakaryocytes. In normal mutant FV can therefore be represented as FV R506Q, plasma,~60% of protein S is complexed to C4b-but is more often referred to as FV Leiden. binding protein, while 40% circulates in its functionally The FV Leiden mutation was observed as an active free form [20] . Both free protein S and complexed protein S can bind to APC, but only the free Correspondence and offprint requests to: Priv. Doz. Dr. B. Hocher, form has cofactor activity.
Haemodialysis patients with hereditary thrombogenic defects
Heterozygous APC-resistant haemodialysis patients seem not to have an additional risk for thrombosis, whereas the risk is not known for homozygous patients [1] . A functional protein S deficiency in haemodialysis patients has been thought to occur most probably as a result of a synthesis defect by impaired endothelial cells due to vascular calcifications [2] caused by secondary hyperparathyroidism, which is very common in these patients. Free protein S deficiency could be determined as an additional risk factor for thrombosis in haemodialysis patients [2] . The management of inherited thrombogenic disorder is also complicated by the fact that renal transplant failure occurs earlier, with a 3.5-fold higher risk for 1 year graft loss comidentification of families with congenital protein S pared with controls [38] . deficiency. In these families, the affected heterozygous subjects are at risk of developing venous thromboembolic disease. The clinical symptoms of congenital Case protein S deficiency are very similar to those of congenital protein C deficiency.
The 36-year-old female non-smoking haemodialysis Three types of protein S deficiency have been patient was admitted in our hospital with an occlusion reported by Comp et al. [21] and Mannucci et al. [22] .
of her cimino A-V shunt. This was the tenth shunt (i) Type I shows decreased levels of free protein S thrombosis within 2 years. antigen, total protein S antigen and protein S activity;
The renal disease was first diagnosed in 1981 as (ii) type II shows normal levels of free protein S chronic glomerulonephritis. A biopsy was not perantigen and total protein S antigen, but a decreased formed. The patient at this time had no complaints. level of protein S activity, and (iii) type III shows One year later (1982), the patient underwent elective decreased levels of free protein S antigen and protein sectio caesarea due to oedema and hypertension during S activity, but a normal level of total protein S antigen.
the last 3 months of pregnancy. She delivered a healthy Venous thrombosis is the most common manifestason. In 1984, she was started on haemodialysis. Three tion of protein S deficiency [23] . Aortic [24] and years later (1987), a kidney transplantation was percoronary thrombosis [25] , stroke [26 ] and renal vein formed, but the transplant function failed due to severe thrombosis [27] have also been reported. About thrombosis of the graft vein. A transplantatectomy 0.8-3% of thromboembolic cases are thought to be was done 12 days later. A second kidney transplantadue to protein S deficiency [28] , and a genetic defect tion was performed successfully in 1988. This time the resulting solely in a protein S deficiency is estimated patient received heparin (250 IE/h i.v.) for 3 weeks. to lead to thromboembolic incidences in 19% of cases This graft initially worked well, but later kidney func- [29] . The prevalence of protein S deficiency is 0.075% tion was characterized by a slowly progressive [30] . declaiming function. Biopsy revealed signs of chronic rejection. The patient became hypertensive in 1995 and The combination developed a secondary hyperparathyreoidism (parathormon was 921 ng/ml; normal range: <70 ng/ml ). The combination of APC resistance and protein S deficiency leads to thromboembolism in 72% of cases A partial parathyreoidectomy was performed in April 1996. Since May 1996 the patient had again needed [29] . The estimated prevalence of this combination would be~0.004% if the prevalence of APC resistance haemodialysis. At dialysis, our patient became hypotensive. In 1996, a dyslipidaemia was detected (cholescould be considered as 5%. Several trials show no correlation between APC resistance and protein S level terol: 9.41 mmol/l ).
A thrombectomy of the old cimino shunt was per-[31], although Koeleman et al. reported a high prevalence of FV Leiden mutation among protein S-deficient formed. Ten weeks later, a shunt thrombosis occurred.
A further correction of the shunt's situation was patients, probably due to pre-selection of the patients [32] . Nevertheless, there is evidence for possible misdia-impossible so a new cimino shunt had to be placed.
Three months later, a further shunt thrombosis gnosis of APC resistance as protein S deficiency [33] , and this has to be considered when reviewing reports occurred and the thrombectomy initially was successful. Therapy with oral anticoagulants (MarcumarA) published prior to the discovery of APC resistance. A combination of both inherited abnormalities of the started; INR was between 2 and 3. Two thrombotic events of the cimino shunt followed in December 1997. coagulation system leading to severe venous thrombosis [34] [35] [36] [37] seems to be a very rare event.
Since all native vessels were occluded or not suitable, a plastic graft shunt was made at the end of December her second period on haemodialysis (1996-1998). A congenital form of protein S deficiency should have 1997. However, further thrombotic events occurred: one in February, two in March, two in July and one led to shunt thrombosis also during her first period on haemodialysis (1984) (1985) (1986) (1987) (1988) . However, we have to conin October 1998. MarcumarA therapy was stopped in June 1998, because this treatment obviously did not sider that some of the thrombotic events during her second period on haemodialysis occurred in a plastic prevent further shunt thrombosis.
A heterozygous inherited APC resistance with FV graft. Plastic grafts have a higher risk of a thrombotic occlusion, thus being an additional risk factor for Leiden was determined by genotyping and functional analysis of APC resistance. In addition, a protein S our patient.
The combination of APC resistance and protein S deficiency was found by clotting test and by enzymelinked immunosorbent assay ( ELISA) (both from deficiency in a haemodialysis patient presents a challenge for the treating physician. Several point have to Boeringer Mannheim). In addition, we could not detect an inhibitor of protein S. No thrombotic events in the be considered. (i) Life-long anticoagulation therapy with heparin might offer a possible solution since family were reported. We determined, using the same methods, a pathological APC resistance ratio of 1.5 in heparin does not interfere with the impaired synthesis of the protein S/protein C system in our patient. the father and a normal ratio in the mother. This was confirmed by sequencing. No pathological plasma (ii) Oral anticoagulation, on the other hand, could not prevent the thrombotic events in our case, probably levels of protein S were assessed in either of the parents. The last laboratory findings were (oral anticoagulation due to the additional inhibition of the synthesis of both protein C and the residual protein S. They are was paused): Quick 105%; PTT 33.9%; AT III 118%; fibrinogen 334 mmol/l; protein C 91%; protein S 6%; both vitamin-K-dependent factors, which are synthesized in the liver and in the endothel cells [2, 20] . This APC resistance 1.5; FV 155%; FVIII 404%; vWF 294%.
The patient underwent successful cadaver kidney might explain that we observed multiple thromboses in our patient even when the oral anticoagulation transplantation in November 1998. In order to prevent early thrombosis of the graft, we treated our patient therapy had the result of INR 2.5. Only a few reports have described a phenotypic correction of APC resistwith heparin (300 IE/h i.v.) for the first 3 days after transplantation and continued thereafter with low ance following orthotopic liver transplantation [39, 40] .
In summary, we report on a patient with heterozygmolecular heparin s.c. (100 antiXa/kg/day).
ous APC resistance and secondary protein S deficiency, most probably due to secondary hyperparathyroidism,
Discussion
suffering from recurrent shunt thrombosis. To our knowledge, this is the first report describing this condition. However, we would expect that this pathophysiolThrombosis of the A-V shunt is the leading cause of hospital admission in haemodialysis patients. APC ogical situation might be rather frequent, since secondary hyperparathyroidism in haemodialysis resistance is the most common genetic cause of thrombophilia. A heterozygous form of APC resistance does patients is often seen, and the heterozygous form of APC resistance is seen in~5% of the entire population. not represent an additional risk for thrombosis in haemodialysis patients, whereas the risk is not known for the homozygous patients [1] . On the other hand,
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